

implants

international magazine of oral implantology

research

Professional implant
management

case report

Combining standard
and ultrashort implants in
full-mouth rehabilitation

case report

Interproximal root spreading
for narrow implant placement





Tissue Level Implants with Zirconia Collar



Digital workflow at
your fingertips

Zirconia crown made by Index
One milling machine

Aesthetic gingival area

Zirconia collar

Gingival integration
& Osseointegration

Bone area

Pure Titanium body



Unique, like your smile

The Z1® implants are medical devices intended for placement in the mouth, in case of partial or total tooth loss, by qualified healthcare professionals. These medical devices are regulated health products which, in accordance with this regulation, bear the CE marking. These dental implants are manufactured in France by Sudimplant SAS, owner of the Z1® trademark. For any information, please contact your dentist.



Find us online
www.tbr.dental

Dr Georg Bach
President of DGZI

Dr Rolf Vollmer
First Vice President and Treasurer of DGZI



To be continued . . .

Through the 3rd Future Congress for Dental Implantology, the German Association of Dental Implantology (DGZI) planned to celebrate its 50th anniversary this year in its founding city of Bremen. The outstanding congress concept, the streaming of live surgeries, the myriad of scientific lectures delivered by renowned speakers, the table clinics with hands-on character, the digital poster presentation and the now traditional get-together would have made for a truly extraordinary scientific event for continuing professional development. At the congress, attendees would have had the opportunity to reflect on half a century of oral implantology in Germany, which in its essence is deeply entwined with the work of DGZI. The objective was to highlight major current developments and to envision what implantology of the future could look like. The congress would have been the perfect platform for collegial exchange, discussions with experts and fruitful talks with industry representatives.


In the past months, a great deal of effort has been invested in the preparation of the congress. Time and again, attempts have been made to adapt the concept to the dynamically changing COVID-19-related restrictions on public gatherings and stipulations regarding hygiene measures. These unpredictable circumstances have made it increasingly difficult to realise an event of such magnitude and complex character. After all, personal exchange and close interaction between partic-

ipants is the foundation that the Future Congress is based on. Additionally, the limited number of participants allowed in the city of Bremen at the time of writing would have meant that about half of the congress registrations would have had to have been cancelled. In view of the dramatically surging number of infections, there was little hope that the situation would change and hence, considering the importance of protecting the health of all those involved, DGZI ultimately had to reschedule the congress.

DGZI would like to take this opportunity and thank all participants, speakers, industry experts and the organiser, OEMUS MEDIA. Without their trust and committed support, this long-planned project would never have come so far. We invite you to follow the continuing efforts at DGZI, and we already look forward to welcoming you to the 3rd Future Congress for Dental Implantology—our 50th International Annual Congress—in 2021.

The fact that not everything has had to be subordinated to the pandemic is underlined by this year's fourth issue of *implants—international magazine of oral implantology*. We wish you and your entire practice staff an enlightening read, good health and mental resilience for the weeks and months to come.

Yours, Drs Georg Bach & Rolf Vollmer



Cover image courtesy of TBR Dental Group
www.tbr.dental



editorial

- To be **continued** ... 03
Drs Georg Bach & Rolf Vollmer

research

- Professional** implant management 06
Marie-Therese Heberer & Prof. Nicole B. Arweiler
- SEM **investigation** of implant surface characteristics 14
Drs Branislav Fatori & Inge Schmitz

case report

- Mandibular **dentigerous** cyst 16
Drs Fernando Duarte & Carina Ramos
- Combining **standard** and **ultrashort** implants in full-mouth rehabilitation 22
Drs Giovanni Ghirlanda, Michele Vasina & Laura C. Campos
- Interproximal **root spreading** for narrow implant placement 28
Dr Mauro Marincola, Dr Laura Murcko, Dr Giorgio Lombardo & Prof. Rolf Ewers
- Immediate **placement** of a new fully tapered tissue-level implant 32
Dr Mario Rocuzzo

practice management

- Practice **strategies** in the time of the coronavirus 34
Dr Anna Maria Yiannikos

news

- manufacturer news 36
- news 40

about the publisher

- imprint 42



NovoMatrix™ Reconstructive Tissue Matrix – the next generation material

NovoMatrix™ Reconstructive Tissue Matrix is an acellular dermal matrix derived from porcine tissue intended for soft tissue applications. The proprietary LifeCell™ tissue processing is designed to maintain the biomechanical integrity of the tissue, which is critical to support tissue regeneration.

Indications

- Localized gingival augmentation to increase keratinized tissue (KT) around teeth and implants
- Alveolar ridge reconstruction for prosthetic treatment
- Guided tissue regeneration procedures in recession defects for root coverage

Product features

- Consistent thickness (1 mm)
- Pre-hydrated
- Controlled source

www.biohorizonscamlog.com

Professional implant management

A balance between thorough but gentle cleaning

Marie-Therese Heberer & Prof. Nicole B. Arweiler, Germany

The treatment of peri-implant disease remains a great challenge for the practising dentist. In spite of current guidelines, a direct therapy recommendation for treating diseased implants is still lacking. Owing to demographic change and the wide range of indications for implants, peri-implant disease is becoming an increasingly relevant problem in everyday practice. Since peri-implantitis is an irreversible disease that can lead to pain, severe aesthetic impairments and implant loss, it is necessary to adequately care for implants and treat the first signs of peri-implant inflammation at an early stage.

On peri-implantitis and how it can occur

Peri-implant health and disease were classified in the context of periodontal and peri-implant diseases and conditions at the joint World Workshop of the American Academy of Periodontology and the European Federation of Periodontology in 2017 for the first time.¹ Table 1 provides an overview of the case definition of peri-implant health and peri-implant disease. Peri-implant health, on the one hand, is clinically defined as the absence of signs of inflammation such as erythema, bleeding on probing, swelling and suppuration. Peri-implant diseases, on the other hand, are classified as biofilm-associated diseases that are clinically conspicuous by inflammatory changes in peri-implant soft tissue accompanied by bleeding on probing and/or suppuration.² Compared with measurements at the time of insertion of the superstructure (baseline), which are caused by progressive bone loss that goes beyond the initial remodelling, peri-implantitis shows increased probing depth.³ Given the lack of radiographs and probing depth measurements at baseline (directly after superstructure insertion), radiographic ev-

idence of a bone level of ≥ 3 mm and/or a probing depth of ≥ 6 mm connected with heavy bleeding and/or suppuration after probing are sufficient for the diagnosis of peri-implantitis. In contrast, peri-implant mucositis does not involve any decrease of the crestal bone level beyond the initial remodelling after insertion of the implant.

Similar to periodontitis, which is almost always preceded by chronic gingivitis, peri-implant mucositis exists before peri-implantitis arises. As mentioned earlier, this is marked by signs of inflammation, but does not yet involve bone resorption. Peri-implant mucositis is strongly associated with biofilm, which makes it—fortunately—reversible by adequate biofilm management. The transition to peri-implantitis is fluid and cannot be diagnosed clearly, and this must be taken into account when selecting the treatment approach. The cause of the progression of peri-implant mucositis to peri-implantitis has not been identified yet,¹ but the risk factors described later certainly play a role. If no elaborated therapy for peri-implantitis is provided, rapid, often non-linear progression of bone resorption and inflammation occurs,⁴ presumably with faster spread and higher prevalence than in periodontitis. Peri-implantitis can already occur at the beginning of the maintenance phase, even shortly after the implantation. Noticeable problems can be expected after five years, and 20 % of patients require peri-implantitis therapy after five to ten years.⁵ Some experts report the start of the disease two to three years after implantation.⁶

Risk factors for peri-implantitis

The aetiology of peri-implantitis is comparable to that of periodontitis. Both are multifactorial events that are modi-

	Peri-implant health	Peri-implant mucositis	Peri-implantitis
BOP and/or suppuration with gentle probing (possibly increased PD compared with baseline)	–	+	+
Bone loss	–	–	+

Table 1: Case definition of peri-implant health and disease according to the new classification.¹

fied by co-factors multiple times. Bacterial (plaque) biofilm accumulation, which causes an initial immune response (inflammation), can be seen as the main cause. It is directly related to the oral hygiene of the patient. It is crucial to avoid restorations with difficult-to-clean niches—especially in older patients—which requires a close co-operation between dentist and dental technician.⁷ Poor cleanability of the implant and its superstructure and thus biofilm accumulation as well as cement residue are termed as local modifying factors.

Patients who already have a severe form of periodontitis prior to implant placement, have poor biofilm control and are not integrated into a regular aftercare system (supportive periodontal therapy) can be classified as a high-risk group.⁸ Patients with periodontitis have been shown to have a significantly higher rate of peri-implantitis occurrence within ten years (28.6 % vs 5.8 %) and thus a significantly lower success rate (71.4 % vs 94.5 %).⁹ Therefore, healthy periodontal conditions through systematic periodontitis therapy and a high-frequency recall system must be guaranteed, even before implant placement.¹⁰ In other words, only if both conditions are met is the patient ready for implants. Reducing the accumulation of bacteria immediately prior to implant placement is recommended, for example mucosal antiseptics with chlorhexidine rinsing solution. Subsequently, wound healing must be optimised.¹¹ In addition, smoking cessation should take place before implant placement.^{8, 12} The development of peri-implantitis has thus far been considered to be particularly favoured by the combination of pre-existing periodontal disease and smoking.^{5, 13–15} Diabetes mellitus and interleukin-1 polymorphism, especially, have been systemic risk factors so far.^{8, 16–18} A recent paper evaluates excess cement as a potential risk factor/indicator, but states that data identifying “smoking” and “diabetes” as risk factors are so far inconclusive.⁴

Differences in the inflammatory response

Whether the bacterial spectrum in peri-implantitis is different from that in periodontitis, which would also result in a slightly different immune response, is matter of much discussion. Implants of titanium or ceramic have a bio-compatible surface, but no biological surface. For osseointegration, they should have a large-volume, sponge-like surface. However, these surfaces, if they are exposed or become accessible to bacteria, offer perfect conditions for bacterial proliferation. A Swiss research group compared the inflammatory reaction to 21 days of plaque accumulation on the tooth and implant in an experimental gingivitis/mucositis model using plaque and bleeding indices and inflammatory markers.¹⁹ While no significant differences in plaque index between tooth and implant were revealed, significant differences were found for the gingival index and inflammatory markers (active matrix metalloproteinase-8 and interleukin-1 β). Both were sig-



Fig. 1: Interdental brushes have to be selected individually—even for implants. The fitting should be part of the instruction during prophylaxis sessions.

nificantly higher for implants than for teeth despite very similar plaque accumulation. This is probably due to the lack of a periodontal ligament on implants.¹⁹

On peri-implantitis prophylaxis

The most important pillar should be the avoidance of peri-implant disease. Problematically, just as with periodontitis, peri-implant disease is rarely conspicuous at the initial inspection, is largely painless and shows few symptoms. For this reason, the patient is not able to make a self-diagnosis, which often leads to a delayed diagnosis and, in particular, a significantly late start of therapy. The irreversibility of tissue loss explains the poor prognosis. For this reason, dentists and prophylaxis staff must prioritise precaution, that is, optimum maintenance care of the inserted implant and its superstructure. Prophylaxis for the implant does not only mean prophylaxis sessions every three to six months but also optimal instruction and motivation for good oral hygiene at home for the whole year.¹²

Home care prophylaxis measures

Motivating patients by staining the teeth with a plaque disclosing agent is a proven method. This enables the dentist to specifically show the patient where an improvement in home biofilm management is necessary. The use of interdental brushes and the explanation of their application should be strongly recommended here (Fig. 1). Alternatively, soft picks are offered on the market. These are quite practical and usually cheaper, but the scientific data for an equivalence to interdental brushes is not yet available. In addition to mechanical biofilm control at home, chemical biofilm management can support measurements—especially for patients who cannot perform adequate cleaning of their implants.²⁰ This S3 level guideline²⁰ on “home care, chemical biofilm management” highlighted patients with implants and implant-supported dentures as those with a particularly high risk of inflammatory changes (gingivitis or mucositis). While 0.1–0.2 % chlorhexidine digluconate solutions are recommended



Fig. 2: Powder air polishing systems with low-abrasive powder (glycine and erythritol powder) clean gently.

for short-term (14-day) intensive bacterial reduction and therewith reduction of an acute inflammatory event, mouthrinses containing 0.06 % chlorhexidine, a special formulation of essential oils, a formulation with amine fluoride or stannous fluoride, or a formulation with cetylpyridinium chloride can support insufficient mechanical oral hygiene for a variety of reasons. For implants, the specific application of a 1 % chlorhexidine gel is also suitable. Regular professional mechanical biofilm removal by trained persons as well as an improvement of biofilm management at home are the basis for the success of the therapy, both for prevention and in the case of already existing peri-implantitis.^{7, 17, 21–23}

Professional prophylactic measures

In addition to these prophylactic measures, the practitioner must identify the systemic and local risk factors already mentioned and at least provide the impetus to remove them, which should be done before implant placement if possible.^{8, 17} In order to confirm success, but also to be able to recognise the necessity of further therapy measures, regular check-ups including measurements are also indispensable for the dentist throughout the patient's life. Measurements, supragingival and, where necessary, subgingival cleaning (scaling and root planing) should be performed up to four times a year and should be carried out at regular intervals. Checking the complete periodontal status is recommended at least once a year in the case of six-monthly follow-up intervals and at least twice a year in the case of three-monthly intervals.

Designing supportive peri-implant therapy

Good oral hygiene of the patient as well as regular, life-long maintenance care sessions at intervals of three to six months are the key to long-term success. The regular recording of findings in order to determine both the oral hygiene status and the attachment level to implants and to diagnose changes at an early stage are the basis for this. Part of each session of supportive peri-implant therapy should include supragingival measures as well as regular motivation and instruction of the patient on good home biofilm management. An essential part of these maintenance sessions should, if necessary, be devoted to subgingival instrumentation of the implants. Necessary

cleaning must not be omitted owing to fears of possible surface damage. A compromise must be found between protecting the implant by gentle instrumentation to avoid deep scratches on its surface and thorough cleaning. Rough implant surfaces show not only more biofilm but also a more pathogenic flora, whereas surfaces that are too smooth disrupt soft-tissue attachment and fibroblast attachment. Hence, a good balance between bacterial adhesion and soft-tissue adhesion must be found.²³ The practitioner has various therapy options for subgingival cleaning. Recently, Schmidt et al. conducted a series of studies to examine cleaning options for their balance between bacterial adhesion and soft-tissue adhesion.^{24–26} The following conclusions were drawn:

- If curetting is necessary (i.e. radiographically visible deposits), titanium curettes should be used instead of the conventional steel curettes, as they are much gentler on titanium surfaces.
- Ultrasonic instruments with a plastic coating hardly change the surface roughness, but should be reserved for the removal of hard deposits.
- Air-powder prophylaxis units with low-abrasive powder (glycine and erythritol powder; air polishing) are ideal for biofilm removal. At probing depths of up to 5 mm, it is even possible to blast into the sulci. At higher probing depths, nozzle attachments should be used (Fig. 2). The spray jet of the nozzles is deflected laterally so that it does not radiate apically and the risk of emphysema formation is avoided.

The mentioned approaches (titanium curettes, ultrasonic instruments, air polishing with low-abrasive powder) are gentle on the implant surfaces, show good clinical results and do not differ significantly from each other. Steel curettes lead to greater surface roughness and should therefore be avoided.^{24–26} Considering teeth, the clinical and microbiological results of subgingival air polishing for moderately deep pockets are similar to those of ultrasonic treatment.²⁷ Compared with conventional scaling and root planing, subgingival air polishing actually performs better in terms of its effectiveness in subgingival biofilm removal.²⁸ Good results for subgingival therapy with air polishing have also been demonstrated for implants with peri-implant disease.⁸

The effectiveness of hand instruments, adjuvant air polishing (glycine powder) and ultrasonic scalers has been proved by clinical studies on implants with a significant improvement in clinical parameters (especially bleeding on probing).^{29, 30} The elimination of inflammatory signs should be the primary goal of all procedures.^{17, 31} In addition to cleaning, an individual risk analysis and, if possible, the elimination of risks must also be part of maintenance care if they have developed after implant placement. This includes advice on quitting smoking but also an exchange with the attending physician or internist to optimise the control of any diabetes that may be present. Subgingival

copa
SKY 
IMPLANT SYSTEM

The innovative hybrid connection
for sophisticated restorations!



Conical?
Parallel?

The new
copaSKY!

For subcrestal position | Unique prosthetic diversity | More space for the gingiva

DENTAL INNOVATIONS
SINCE 1974

bredent^{group}

bredent medical GmbH & Co. KG · Weissenhorner Str. 2 · 89250 Senden · Germany · T: +49 7309 872-441 · F: +49 7309 872-444 · www.bredent-medical.com · @: info-medical@bredent.com